Late breaking abstracts

[2022-LBA-790-ESGO] SENTINEL LYMPH NODE DETECTION WITH MAGTRACE® IN CYSTICAL CANCER

1Marcin Jedryka, 1Andrzej Czekanski, 1Piotr Lepka, 2Tymoteusz Poprawski, 3Marcin Kryszpin, 4Oncological Gynecology, Wrocław Medical University and Lower Silesian Oncology Center, Wrocław, Poland; 2Oncological Gynecology, Lower Silesian Oncology Center, Wrocław, Poland

Introduction This prospective observational study, named POEMCerca (Polish Evaluation of Magtrace® in Cervical Cancer) aims to evaluate efficacy of the Magtrace® system in SLN (Sentinel Lymph Nodes) detection in early stage cervical cancer patients in comparison with the standard of care. The nanoparticle paramagnetic detection systems of SLN have been proved so far to be comparable and non-inferior to the standard procedure of systematic lymphadenectomy in breast cancer and vulvar cancer patients.

Methods 16 patients with stage I cervical cancer received a cervical injection of superparamagnetic iron oxide tracer (Magtrace®). Magtrace® localized and detected SLN with magnetic counts and with visual inspection for their brownish colour. For each SLN the anatomic site, magnetic counts and colour was documented before biopsy. Afterwards, systematic lymphadenectomy – pelvic (PLND) and paraaortic (PALND) – in some cases (high grade tumour and/or adenocarcinoma) was performed as the standard of care.

Results SLN were detected in every patient. Bilateral SLN were found in 87.5% of cases. The mean SLN count per patient was 3.9. All SLN were assessed as brownish stained. In one SLN micrometastasis was detected. Statistic results have been presented in the table 1.

Abstract 2022-LBA-790-ESGO Figure 1

<table>
<thead>
<tr>
<th>Statistical result</th>
<th>Value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>6.25%</td>
<td>0.16% to 30.23%</td>
</tr>
<tr>
<td>Specificity</td>
<td>100.00%</td>
<td>79.41% to 100.00%</td>
</tr>
<tr>
<td>Negative Likelihood</td>
<td>0.94</td>
<td>0.83 to 1.06</td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td>100.00%</td>
<td></td>
</tr>
<tr>
<td>Negative Predictive Value</td>
<td>90.57%</td>
<td>89.43% to 91.59%</td>
</tr>
<tr>
<td>Accuracy</td>
<td>90.62%</td>
<td>74.98% to 98.02%</td>
</tr>
</tbody>
</table>

Conclusions This preliminary study showed efficient Magtrace® detection of SLN in early stage cervical cancer patients which is not inferior to the standard of care.

[2022-LBA-1282-ESGO] IDENTIFYING WOMEN WITH EARLY-STAGE CYSTICAL CANCER AT LOW RISK OF LYMPH NODE METASTASES, IN A LARGE INTERNATIONAL COHORT – A LOGISTIC REGRESSION ANALYSIS, WITHOUT SHARING PRIVACY-SENSITIVE PATIENT DATA

11Hans Wenzel, 3Anna Norberg Hardie, 5Ruud Belkiers, 3Henrik Falconer, 2Claus Hodgall, 4Pernille Jensen, 11Johan Valery Lemmens, 3Frank Martin, 1Arturo Moncada, 2Hans Nijman, 1Maaike van der Aa, 21Tine Schnack, y (DANDELION) research group Dutch, dANish and sweDish gynaEcological ONcologis, 3Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKN), Utrecht, Netherlands; 2Department of Obstetrics and Gynaecology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands; 3Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden; 4Department of Women’s and Children’s Health, Kalmar Institute, Stockholm, Sweden; 4GROW school for oncology and developmental biology, Maastricht University Medical Centre+, Maastricht, Netherlands; 3Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, Netherlands; 6Department of Gynecology, Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark; 7Department of Gynecology, Aarhus University Hospital, Aarhus, Denmark; 8Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 9Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, Netherlands; 3Department of Gynaecology, Odense University Hospital, Odense, Denmark

Introduction Standard treatment of early-stage cervical cancer is radical hysterectomy with pelvic lymphadenectomy. However, a generic benefit of systematic lymphadenectomy is questionable, as most women will not have metastatic nodes. This study aimed to classify the most important risk factors of lymph node metastases (pN+) and to identify a group of women at low risk of pN+, in a large cohort of Danish, Swedish and Dutch women, using federated learning.

Methods Women diagnosed with cervical cancer between 2005–2020 were identified from nationwide population-based registries: the Danish Gynaecological Cancer Database, Swedish Quality Registry of Gynaecologic Cancer and Netherlands Cancer Registry. Inclusion criteria were: squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma; FIGO 2009 stage IA2, IB1 and IIA1; treatment with radical hysterectomy and pelvic lymph node assessment. We applied privacy-preserving federated logistic regression to identify risk factors of pN+ (figure 1). Significant factors were used to identify a low-risk group (pN+ &le;5%).

Results A total of 3,606 women were included. The most important risk factors of pN+ were lymphovascular space invasion (LVS1) (odds ratio [OR] 5.16, 95% confidence interval [CI] 4.59–5.79), tumour size 21–40 mm (OR 2.14, 95% CI 1.89–2.43) and depth of invasion >10 mm (OR 1.81, 95% CI 1.59–2.08)). Tumours without LVS1, a size £20 mm and a depth of invasion ≤10 mm were associated with a low risk of pN+ (2%, 95% CI 2–3%) (table 1).
Conclusions LVS1, tumours size and depth of invasion were the most important risk factors of pN+. Based on that, we identified a group at very low risk of pN+, in whom sentinel lymph node mapping should be considered to replace radical pelvic lymphadenectomy.


Introduction MIS has been abandoned in many centers for cervical cancer treatment after publication of the LACC trial in 2018. Several critics and theories emerged afterward. Our study looked at data of a single large volume institution. Disease free survival (DFS) and mortality rates were compared for both surgical approaches.

Methods We retrospectively reviewed all surgical cervical cancer cases from 2006 to 2017 of the Centre Hospitalier de l’Université de Montréal. Only patients treated by Minimal Invasive Surgery (MIS) or laparotomy were included. We compared cohorts’ characteristics and survival outcomes for MIS and laparotomy. Descriptive data is presented in means, standard deviations, and percentages. Kaplan-Meier was used to generate disease free survival (DFS) and overall survival (OS) curves; log-rank was used to compare curves. Survival outcomes of the use of intrauterine manipulator were also investigated. Statistical significance was 0.05.

Results 257 patients were included (94 robotic, 38 laparoscopy, 125 laparotomy). Patients’ characteristics did not significantly differ among groups. Histology was 50.6% squamous cell carcinoma, 35.4% adenocarcinoma, 3.9% adenosquamous and 10.1% other subtypes. Patients were FIGO stages IA (51.0%), IB (43.1%) and IIA or more (5.9%). Median follow-up was 161 months. Intrauterine devices were used in 70.2% of the MIS group. 48.8% had no residual disease at surgery. No differences in intra-operative, post-operative complications and readmission rates between MIS and laparotomy was observed. Total cohort intra-operative and post-operative complications rates were respectively 4.5% and 25.2%. Recurrence rates and death rates were significantly lower for MIS than for laparotomy approach (respectively 1.5% vs 8.1%, p=0.013, 1.5% vs 4.8%, p=0.043). Disease-specific mortality rate did not statistically differ (MIS=1.5%, laparotomy =4.8%, p=0.121).

Conclusions Selected cervix cancer patients may benefit from MIS. Further studies are needed.